Among the neglected and downtrodden stocks in the health care landscape, there lies a glimmer of opportunity for astute investors to uncover undervalued gems.
One tool that shines a light on potential is the RSI, a barometer that gauges a stock’s vigor on up days against its mettle on down days. This metric offers traders a glimpse into a stock’s probable short-term trajectory. When the RSI dips below 30, it signifies oversold conditions, as per market voices.
Let’s delve into the names making waves as prime candidates for a market resurgence with their RSIs hovering close to or below the 30-mark.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
Spotlight: Progyny Inc (NASDAQ: PGNY)
- News of a client opting out of services on September 19 sent shockwaves through Progyny Inc.’s shares, marking a 32% decline over the last week with a 52-week low of $13.93.
- RSI Value: 26.50
- PGNY Price Action: Progyny’s stock managed to inch up by 1%, closing at $16.62 on Friday.
Indivior PLC (NASDAQ: INDV)
- An announcement on September 4 regarding Aelis Farma’s Phase 2B study stirred movement in Indivior PLC’s shares, marking a 52-week low of $9.14.
- RSI Value: 25.92
- INDV Price Action: Indivior faced a 2.1% descent, closing at $9.48 on the last trading day.
Gem Potential: Moderna Inc (NASDAQ: MRNA)
- A milestone on September 17 showcased Moderna Inc’s prowess as Health Canada approved its SPIKEVAX vaccine to combat COVID-19, with a focus on the KP.2 variant. The company stands ready to supply doses to the Public Health Agency of Canada imminently. Dr. Shehzad Iqbal, Moderna Canada’s country medical director, urged individuals to prioritize staying updated with their COVID-19 shots amid escalating infection rates. Moderna’s shares took a 20% nosedive in the past month, hitting a 52-week low of $62.55.
- RSI Value: 28.17
- MRNA Price Action: Moderna’s stock witnessed a 3.4% dip, concluding at $65.69 at the week’s close.
Read Next:
Market News and Data brought to you by Benzinga APIs